Aldeyra Therapeutics (ALDX) Enterprise Value (2014 - 2026)

Aldeyra Therapeutics (ALDX) has reported Enterprise Value for 13 consecutive years, with $83.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value fell 33.22% year-over-year to $83.4 million; the trailing twelve-month figure through Jun 2026 stood at $83.4 million (down 33.22% YoY), and the FY2025 full-year result was $241.6 million, up 39.17% from the prior year.
• Enterprise Value advanced to $83.4 million in Q2 2026 per ALDX's latest filing, from $36.9 million in the prior quarter.
• Across five years, Enterprise Value topped out at $418.8 million in Q1 2023 and bottomed at $30.5 million in Q2 2024.
• Historically, Enterprise Value has averaged $171.1 million across 5 years, with a median of $161.2 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value tumbled 91.08% in 2024, then surged 401.14% in 2025.
• Over 5 years, Enterprise Value stood at $233.3 million in 2022, then sank by 72.16% to $65.0 million in 2023, then jumped by 167.27% to $173.6 million in 2024, then jumped by 39.17% to $241.6 million in 2025, then tumbled by 65.48% to $83.4 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $83.4 million, $36.9 million, and $241.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.